<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The aetiology of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) remains elusive in the majority of cases </plain></SENT>
<SENT sid="1" pm="."><plain>There is experimental evidence to show that <z:chebi fb="0" ids="35664">HMG-CoA reductase inhibitors</z:chebi> (<z:chebi fb="0" ids="35664">statins</z:chebi>) may inhibit proliferation and induce cause <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells and although some clinical studies have suggested that <z:chebi fb="0" ids="35664">statins</z:chebi> may protect against the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, this has not been a consistent finding </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore we have examined any potential protective effects of <z:chebi fb="0" ids="35664">statins</z:chebi> by comparing <z:chebi fb="0" ids="35664">statin</z:chebi> use in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> against a control group </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: This was a case-control study examining <z:chebi fb="0" ids="35664">statin</z:chebi> use in symptomatic patients attending for diagnostic colonoscopy </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="35664">Statin</z:chebi> use was compared between patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and a control group, who had <z:hpo ids='HP_0000001'>all</z:hpo> had <z:mpath ids='MPATH_458'>normal</z:mpath> colonoscopy </plain></SENT>
<SENT sid="5" pm="."><plain>Structured interviews and clinical records notes were used to determine drug exposure </plain></SENT>
<SENT sid="6" pm="."><plain>Logistic regression was used to compare <z:chebi fb="0" ids="35664">statin</z:chebi> exposure and correct for confounding factors </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: There was a significant inverse association between previous <z:chebi fb="0" ids="35664">statin</z:chebi> use and a diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (OR = 0.43 (95% confidence interval 0.25 - 0.80), p&lt;0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>This inverse association was stronger with higher <z:chebi fb="0" ids="35664">statin</z:chebi> doses (OR = 0.19 (0.07 - 0.47), p&lt;0.01) and greater duration of <z:chebi fb="0" ids="35664">statin</z:chebi> use (<z:chebi fb="0" ids="35664">statin</z:chebi> use &gt;years: OR = 0.18 (0.06 - 0.55), p&lt;0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="35664">Statins</z:chebi> use was associated with a protective effect against the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>This effect is associated with a significant dose and duration response </plain></SENT>
<SENT sid="11" pm="."><plain>These findings need to be repeated in other observational studies before an interventional study can be considered </plain></SENT>
</text></document>